Motor Neurone Disease Trial, Recruiting NCT06810219 Sponsor: Cognixion Condition: Motor Neurone Disease
Back to Motor Neurone Disease

Motor Neurone Disease Trial, Recruiting

NCT06810219
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • A family member, caregiver, or other trusted person (called a Legally Authorised Representative) must be available to give consent on the participant's behalf and be present throughout the study
  • There must be a specific person available who can be trained to use the Cognixion communication system
  • The participant must understand English fluently
  • The participant must be 18 years of age or older
  • The participant must have ALS (also known as Motor Neurone Disease) and have a need for an assistive communication device
  • The participant must be able to open their eyes on purpose and hold them open independently for a period of time (confirm with trial site for exact duration required)
  • The participant must have at least one other way to communicate beyond the Cognixion device, such as using their voice, nodding their head, blinking, or raising their eyebrows — at minimum, a reliable way to signal "Yes" and "No"

Who may not be able to join:

  • People who have difficulty understanding English, whether due to not being fluent or due to a language condition such as aphasia (a communication disorder caused by brain damage)
  • People who are severely hearing impaired or deaf
  • People who have a sensitivity to flashing lights
  • People with a history of epilepsy or seizures
  • People with vision conditions that limit their field of vision, such as glaucoma, double vision, or involuntary eye movements (nystagmus)
  • People with a history of vertigo or other balance and inner ear disorders
  • People whose scalp is prone to irritation, inflammation, injury, or infection

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Chris Principal Investigator, Cognixion

Phone: 8053200774

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Cognixion
Registry
ClinicalTrials.gov
Start date
20 January 2025
Est. completion
30 August 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

System Usability Score; Information Transfer Rate (ITR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov